Occurrence of cryptosporidium parvum IIaA17G1R1 in hospitalized hemato-oncological patients in Slovakia

Elena Hatalova1 · Tomas Guman2 · Veronika Bednarova1 · Vladimira Turcok Simova1 · Mariia Logoida1 · Monika Halanova1

Received: 1 April 2021 / Accepted: 16 August 2021 / Published online: 4 November 2021
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract
This study aimed to determine the presence of cryptosporidiosis in immunosuppressed patients hospitalized at the Clinic of Haematology and Oncohaematology in a form of routine screening. Samples were collected from November 2019 to February 2020, when the first wave of the Coronavirus pandemic occurred in Slovakia. A total of 36 samples were collected from patients hospitalized at the Clinic of Haematology and Oncohaematology, both from the open ward and the intensive care unit. For the diagnosis of cryptosporidiosis, a nested PCR targeting the gp60 gene and the SSU rRNA locus was used. From the 36 samples, Cryptosporidium parvum subtype IIaA17G1R1 was diagnosed in 9 patients (7 from the open ward and 2 from the intensive care unit), all hospitalized at the clinic at the same time, in February 2020. The occurrence of the same species and subtype, Cryptosporidium parvum IIaA17G1R1, in 9 patients hospitalized at the same time, both at the open ward and the intensive care unit may suggest a possible transmission occurred at the clinic.

Keywords Cryptosporidium parvum · Immunosuppression · Malignancies · Transmission · Slovakia

Introduction
Cryptosporidiosis is a significant infection, causing diarrhea among humans. A recent systematic meta-analysis including findings from 221 publications estimates the pooled global prevalence of cryptosporidiosis as high as 7.6%. The prevalence is highest in people living in low-income countries, people with gastrointestinal symptoms, and in children under 5 years of age (Dong et al. 2020). In developed countries, the prevalence ranges from 3.2% in the EU/EEA to 3.8% in the USA (ECDC 2019; CDC 2019). The infection is transmitted mainly via the fecal–oral route. Contaminated water and food are the most important transmission pathways, but Cryptosporidium spp. can also be transmitted by direct contact with an infected human or animal and rarely via air (Hunter and Nichols 2002; Sponseller et al. 2014).

Infections caused by Cryptosporidium spp. are one of the most frequent causes of mortality especially in children under 5 years of age (Lozano et al. 2012; Striepen 2013; Shoultz et al. 2016). To this day, 47 valid Cryptosporidium species and more than 100 distinguished genotypes have been recognized (Holubová et al. 2019; Bolland et al. 2020; Ježková et al. 2021; Zahedi et al. 2021). Human infections are most commonly caused by Cryptosporidium parvum...
and *Cryptosporidium hominis*, although other species and genotypes have been recognized, mainly in humans suffering from immunodeficiency, including *C. meleagridis*; *C. felis*; *C. canis*; *C. cuniculus*; *C. ubiquitum*; *C. viatorum*; *C. muris*; *C. suis*; *C. fayeri*; *C. andersoni*; *C. bovis*; *C. scrofarum*; *C. tyzzeri*; *C. erinacei*; and *Cryptosporidium* horse, skunk, and chipmunk I genotypes (Cacciò et al. 2002; Wolska-Kusnierz et al. 2007; Xiao 2010; Zahedi et al. 2016; Ryan et al. 2016).

In immunocompetent individuals, cryptosporidiosis gastroenteritis is typically self-limiting, and patients usually recover within 2 weeks. On the other hand, chronic diarrhea is present in immunosuppressed patients (Ryan et al. 2016). Immunosuppression, either impaired or constant, is often associated with oncological diseases or their treatment (Śulżyc-Bielicza et al. 2018). Immunosuppression and diarrhea are known side effects in patients undergoing cancer treatment, although few studies were focused on the occurrence of cryptosporidiosis in patients with malignancies (Hassanein et al. 2012).

In this study, we have focused on the occurrence and subtyping of *Cryptosporidium* spp. in patients with hematological and oncological diseases, hospitalized at the Clinic of Haematology and Oncohaematology. This study is also a follow-up to our previous studies about the occurrence of *Cryptosporidium* spp. in immunosuppressed and immunocompetent patients, animals, and in environmental samples to further expand the knowledge of individual species, genotypes, and subtypes circulating in Slovakia (Hasajová et al. 2014; Danišová et al. 2017; Kalinová et al. 2018; Hatalová et al. 2019).

### Materials and methods

From November 2019 to February 2020 a total of 36 samples of feces were collected from diarrheic patients hospitalized at the Clinic of Haematology and Oncohaematology of the Louis Pasteur University Hospital (LPUH) in Kosice. Samples were obtained from patients from the open ward (*n* = 28) and the intensive care unit (ICU; *n* = 8). Samples were transferred to the Department of Epidemiology, Faculty of Medicine of the Pavol Jozef Safarik University in Kosice and stored at -20 °C until analysis. Characteristics of samples according to the date of sampling are summarized in Table 1. Nucleic acids were extracted using the DNA Sorb-B nucleic acid extraction kit (AmpliSense, Russia) according to the manufacturer’s guide. Isolated nucleic acids were stored at -20 °C until the use in PCR. Nested PCR was used for the amplification of the 60 kDa glycoprotein gene (gp60) of *C. parvum* and *C. hominis* since they are the most common species diagnosed in humans (Xiao 2010). After gp60 subtyping, nested PCR using primers targeting the SSU rRNA locus were used for all samples (Leetz et al. 2007) to diagnose other species of *Cryptosporidium* and to ensure that the contamination did not occur during subtyping. For all reactions, a 20 µl mix was prepared using 5× HOT FIREPol Blend Master Mix Ready to Load (Solis BioDyne, Estonia), 0.1 µM of the respective primers, and 5 µl of DNA template. All reactions were carried out in Biometra T1 Thermocycler (AnalyticJenna). Final products of a length of 450 bp (for primers targeting the gp60 gene) or 250 bp (for primers targeting the SSU locus) were analyzed in 1.5% agarose gel dyed with GoodView™ Nucleic Acid Stain in TBE buffer. Positive samples were sent for sequencing. Final sequences were compared with homologous sequences stored in GenBank using BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi). Subtypes of *Cryptosporidium* were assessed according to the rules of subtyping, using serine-coding trinucleotides TCA, TCT, and TCG at the 5′end of the gp60 gene and other repetitive and non-repetitive sequences following the tandem repeats (Xiao 2010).

The consensus sequences were edited and assembled using BioEdit program. Then sequences were aligned using MUSCLE Multiple Sequence Alignment with reference sequences from GenBank. The phylogenetic tree was constructed by maximum likelihood method using the program MEGA-X (Molecular Evolutionary Genetics Analysis software). Bootstrap values were calculated from 1,000 replicates. *C. tyzzeri* was used as an out-group. The phylogenetic tree is represented in Fig. 1.

Parallel to PCR, all patients from this study were tested for common nosocomial strains of bacteria in the microbiological laboratory of the Louis Pasteur University Hospital.

### Table 1 Characteristics of patients' samples according to the date of sampling

| Date of sampling       | No. of samples | Ward          | ICU          |
|------------------------|----------------|---------------|--------------|
|                        |                | Male | Female | Total | Male | Female | Total |
| 18 November 2019       | 8              | 4    | 4      | 8     | 0    | 0      | 0     |
| 27 November 2019       | 10             | 5    | 2      | 7     | 1    | 2      | 3     |
| 28 November 2019       | 3              | 1    | 1      | 2     | 0    | 1      | 1     |
| 23 January 2020        | 6              | 2    | 3      | 5     | 0    | 1      | 1     |
| 24 February 2020       | 9              | 3    | 4      | 7     | 1    | 1      | 2     |
Results and discussion

After PCR, from all 36 samples obtained from November to February, only 9 were positive for *Cryptosporidium* spp. using primers targeting the gp60 gene. All 9 samples where *Cryptosporidium* spp. was detected came from February 2020. In these 9 samples from patients hospitalized at the same time, *C. parvum* subtype IIaA17G1R1 was diagnosed in all cases, both in the open ward and the ICU. Primers targeting the SSU region showed positivity for *C. parvum* only in five samples and also obtained in February 2020. The lower rate of amplification by primers targeting the SSU region in comparison to gp60 primers may be explained by their lower specificity and/or low DNA yield in the isolates. All other samples collected from November 2019 were negative. Parallel microbiological examination by the LPUH laboratory showed that one patient positive for *C. parvum* IIaA17G1R1, hospitalized in the ICU during February 2020, was also suffering from *Klebsiella pneumoniae* type CRE (carbapenem-resistant Enterobacteriaceae). Association between PCR results, dates of sampling, and hemato-oncological diseases of the patients are summarized in Table 2.

*Cryptosporidium* and other opportunistic pathogens are common causes of life-threatening infections with severe or fatal outcomes, especially in immunosuppressed patients.
Cryptosporidium spp. are important parasites in cancer patients, in which a severe form of cryptosporidiosis occurs most frequently (Hunter and Nichols 2002). In recent years, several studies investigated the relationship between cancer and parasites (Oliveira 2014; Samuel 2016). Most studies describe infections caused by Cryptosporidium as a consequence of immunosuppression caused by cancer and its therapy (Sulżyc-Bielicka et al. 2018). These studies were conducted using samples from patients undergoing chemotherapy, therefore fostering the development of opportunistic infections. In these studies, the prevalence of cryptosporidiosis varied from 1.3 to 80% (Hassan et al. 2002; Al-Qobati et al. 2012). A recent study shows that by 2040, the incidence of cancer is expected to rise to 29.5 million new cases per year (Perera et al. 2021). Due to this fact, the probability of the occurrence of opportunistic parasites in cancer patients will increase.

A study conducted in France between the years 2015 and 2017 declared 210 cases of cryptosporidiosis in immunosuppressed patients with solid organ transplantation (51%), HIV (31%), bone marrow transplantation (8%), and malignancy. From the total 210 cases, 80% of the patients were treated with corticosteroids, 19% were on chemotherapy, and 3% had anti-cytokine biotherapy. Patients on mycophenolate mofetil therapy and solid organ transplantation recipients appeared to be the most vulnerable group, especially during the first 6 months after the transplantation (Costa et al. 2018).

Since the 1980s, numerous outbreaks of cryptosporidiosis have been reported in healthcare facilities around the world, including the transmission of the parasites to healthcare workers from immunosuppressed and immunocompetent patients, and between patients (Baxby et al. 1983; Vanden-berg et al. 2012; Feng et al. 2012; Goñi et al. 2015). In our study, from the total 36 samples obtained from November 2019 to February 2020, none was diagnosed with Cryptosporidium spp., except samples obtained in February. In these 9 samples, the presence of the same species and subtype was detected, C. parvum IlaA17G1R1, both in patients from the open ward, and also in patients from the ICU. Before hospitalization, none of the patients showed any clinical signs of cryptosporidiosis, suggesting that a possible transmission of the pathogen occurred at the clinic.

C. parvum IlaA17G1R1 was also diagnosed in previous studies from Slovakia, in immunocompetent humans, and also immunosuppressed adults and children, and animals, suggesting it as a very common subtype in our country (Hatalová et al. 2019). Our study came across limitations. On 11 March 2020, the World Health Organization declared the novel Coronavirus (COVID-19) outbreak a global pandemic (WHO Director-General’s opening remarks at the media briefing on COVID19 -March 2020). On the same date, the Government of Slovakia declared a state of emergency and enhanced restrictive measures countrywide, followed by a lockdown of the country for several months (Uznesenie vlády Slovenskej republiky 147/2020 Z.z.). The hospital and the Clinic of Haematology and Oncohaematology closed to visitors during this period, and sanitary regime was increased. For these reasons, new stool samples and samples of water and smears from the environment were not obtained. This fact led us to postpone the assessment of the source of the infection and the transmission mode until the epidemiological situation becomes more favorable. Repeated sampling could not have been conducted from four of the patients, because they are now deceased.

### Conclusion

The detection of the same species and subtype of Cryptosporidium in 9 patients hospitalized at the Clinic of Haematology and Oncohaematology at the same time, both at the
open ward and on the ICU, indicates that a possible trans-
mission of the pathogen may have occurred. When the sit-
uation allows, we will continue sampling to further monitor the sit-
uation at the Clinic of Haematology and Oncohaematol-
y. In case of repeated occurrences of cryptosporidiosis, we
will conduct an epidemiological investigation to assess the
source of the infection and transmission modes of Crypto-
sporidium spp. in patients suffering from hematono-
logical diseases. Along with the staff, these patients should be
systematically screened for cryptosporidiosis before and
during hospitalization to avoid possible transmission from
healthcare personnel to patients and from patients to person-
nel, eliminating the possibility of an infection.

Acknowledgements This article is dedicated to the memory of Dorota
Hatalova, M.Ed. Special thanks to Mr. Fraser Kyle during the manu-
script preparation and correction.

Funding This study was supported by grants from the Slovak Research
and Development Agency (grant no. APVV-0134) and Scientific Grant
Agency VEGA (VEGA MŠVVaŠ a SAV) (grant no. VEGA 1/0084/18
and VEGA 1/0359/21).

Data availability The data that support the findings of this study are
available on request from the corresponding author. The data are not
publicly available due to privacy or ethical restrictions.

Declarations

Ethics approval Approval for the study was obtained from the Ethics
Committee of the Faculty of Medicine at P. J. Safarik University in
Kosice. The study was performed following the ethical standards as
laid down in the Declaration of Helsinki of 1975 and revised in 2008.

Consent to participate Participation in the study was voluntary and
anonymous, and informed consent was obtained before the medical
examination.

Conflict of interest The authors declare no competing interests.

References

Al-Qobati SA, Al-Maktari MT, Al-Zoa AMB, Derhim M (2012) Intes-
tinal parasitosis among Yemeni patients with cancer. Sana’a,
Yemen. J Egypt Soc Parasitol 42:727–734. https://doi.org/10.
12816/0006356
Baxby D, Hart CA, Taylor C (1983) Human cryptosporidiosis: possible
case of hospital cross infection. Br Med J 287:1760–1761. https://
doi.org/10.1136/bmj.287.6407.1760-a
Bolland SJ, Zahedi A, Oskam C, et al (2020) Cryptosporidium bollandi
n. sp. (Apicomplexa: Cryptosporidiidae) from angelfish (Pterophyl-
lum scarae) and Oscar fish (Astronotus ocellatus). Exp Parasitol
217:. https://doi.org/10.1016/j.exppara.2020.107956
Cacció S, Pinter E, Fantini R et al (2002) Human infection with Crypto-
sporidium felis: case report and literature review. Emerg Infect Dis
8:85–86. https://doi.org/10.3201/eid0801.010269
CDC - Centers for Disease Control and Prevention. Cryptosporidio-
sis summary report — National Notifiable Diseases Surveillance
System, United States, 2018. Atlanta, Georgia: U.S. Department
of Health and Human Services, CDC, 2019. Centers for Disease
Control MMWR Office. Retrieved from https://www.cdc.gov/
healthywater/surveillance/cryptosporidium/cryptosporidium-
2018.html
Costa D, Razakandrainibe R, Sautour M et al (2018) Human crypto-
sporidiosis in immunodeficient patients in France (2015–2017).
Exp Parasitol 192:108–112. https://doi.org/10.1016/j.exppara.
2018.08.001
Danišová O, Valenčáková A, Stanko M et al (2017) Rodents as a
reservoir of infection caused by multiple zoonotic species/geno-
types of C. parvum, C. hominis, C. suis, C. scrofarum, and the
first evidence of C. muskar genotypes I and II of rodents in
Europe. Acta Trop 172:29–35
Dong S, Yang Y, Wang Y et al (2020) Prevalence of cryptosporid-
iosis in the global population: a systematic review and meta-
analysis. Acta Parasitol 65:882–889. https://doi.org/10.2478/s11686-020-00230-1
ECDC - European Centers for Disease Control and Prevention.
Cryptosporidiosis annual epidemiological report for 2017. Sur-
veillance report, 10 Oct 2019. Retrieved from https://www.ecdc.
europa.eu/en/publications-data/cryptosporidiosis-annual-epide
miological-report-2017
Feng Y, Wang L, Duan L et al (2012) Extended outbreak of crypto-
sporidiosis in a pediatric hospital, China. Emerg Infect Dis
18:312–314. https://doi.org/10.3201/eid1802.110666
Gońi P, Almagro-Nievas D, Cieloszyk J et al (2015) Cryptosporidi-
osis outbreak in a child day-care center caused by an unusual
Cryptosporidium hominis subtype. Enferm Infecc Microbiol
Clin 33:651–655. https://doi.org/10.1016/j.eimc.2015.02.003
Hasajova V, Valencakova A, Maleckova B et al (2014) Significantly
higher occurrence of cryptosporidiosis infection in Roma chil-
dren compared with non-Roma children in Slovakia. Eur J Clin
Microbiol Infect Dis 33:1401–1406. https://doi.org/10.1007/
s10096-014-2082-2
Hassan SI, Sabry H, Amer NM, Shalaby MA, Mohamed NA, Gabal-
lah H (2002) Incidence of cryptosporidiosis in immunodeficient
cancer patients in Egypt. J Egypt Soc Parasitol 32:33–46
Hassanein SMA, Abd-El-Latif MMS, Hassanian OM et al (2012) Crypto-
sporidium gastroenteritis in Egyptian children with acute
lymphoblastic leukemia: magnitude of the problem. Infection
40:279–284. https://doi.org/10.1007/s15010-011-0230-5
Hatalová E, Valenčáková A, Luptáková L et al (2019) The first report
of animal genotypes of Cryptosporidium parvum in immuno-
suppressed and immunocompetent humans in Slovakia. Trans-
bound Emerg Dis 66:243–249. https://doi.org/10.1111/tbed.
13009
Holubová N, Zikmundová V, Limpouchová Z et al (2019) Crypto-
sporidium proventriculi sp. n. (Apicomplexa: Cryptosporidiidae)
in Psittaciformes birds. Eur J Protistol 69:70–87. https://doi.org/
10.1016/j.eimc.2019.03.001
Hunter PR, Nichols G (2002) Epidemiology and clinical features of
Cryptosporidium infection in immunocompromised patients. Clin
Microbiol Rev 15:145–154
Iqbal J, Munir MA, Khan MA (1999) Cryptosporidium infection in young
children with diarrhea in Rawalpindi, Pakistan. Am J Trop
Med Hyg 60:868–870. https://doi.org/10.4269/ajtmh.1999.60.868
Ježková J, Limpouchová Z, Prediger J, et al (2021) Cryptosporidium
myocastoris n. sp. (Apicomplexa: Cryptosporidiidae), the spe-
cies adapted to the nutria (Myocastor coypus). Microorganisms
9:. https://doi.org/10.3390/microorganisms9040813
Kalínová J, Valenčáková A, Hatalová E et al (2018) Occurrence of
Cryptosporidium in the water basins of nitra region, slovakia.
Acta Trop 179:36–38. https://doi.org/10.1016/j.actatropica.2017.
12.019
Leetz AS, Sotiriadou I, Ongerth J, Karanis P (2007) An evaluation of primers amplifying DNA targets for the detection of Cryptosporidium spp. using C. parvum HNJ-1 Japanese isolate in water samples. Parasitol Res 101:951–962. https://doi.org/10.1007/s00436-007-0567-y

Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–2128. https://doi.org/10.1016/S0140-6736(12)61728-0

Oliveira G (2014) Cancer and parasitic infections: similarities and opportunities for the development of new control tools. Rev Soc Bras Med Trop 47:1–2

Perera SK, Jacob S, Wilson BE et al (2021) Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: a population-based modelling study. Lancet Oncol 22:182–189. https://doi.org/10.1016/S1470-2045(20)30675-6

Ryan U, Zahedi A, Paparini A (2016) Cryptosporidium in humans and animals—a one health approach to prophylaxis. Parasite Immunol 38:535–547

Samuel F (2016) Opportunistic parasitism: parasitic association with the host that has compromised immune system. J Bacteriol Parasitol 07: https://doi.org/10.4172/2155-9597.1000261

Shoultz DA, de Hostos EL, Choy RKM (2016) Addressing cryptosporidium infection among young children in low-income settings: the crucial role of new and existing drugs for reducing morbidity and mortality. PLoS Negl Trop Dis. 10

Sponseller JK, Griffiths JK, Tzipori S (2014) The evolution of respiratory cryptosporidiosis: evidence for transmission by inhalation. Clin Microbiol Rev 27:575–586. https://doi.org/10.1128/CMR.00115-13

Striepen B (2013) Time to tackle cryptosporidiosis. Nature 503:189–191

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.